Ph.D., Chief Scientific Officer, Exosome Diagnostics
Biography
Johan Skog is a renowned, well-published thought leader in exosome science having pioneered breakthrough discoveries about exosomes and other microvesicles and their vital role as cell messengers and disease proliferators. While at Massachusetts General Hospital/Harvard Medical School, Dr. Skog discovered that tumor-derived mutations can be detected in exosome RNA from serum and other biofluids, findings which were published in Nature Cell Biology in 2008. Additionally, he demonstrated that exosomes serve to deliver messages to other cells, inducing changes favorable to the proliferation of cancer. At Exosome Diagnostics, Dr. Skog continues to pioneer critical advancements in diagnostics and expand the field of exosome biology. Dr. Skog’s research background includes virology, gene therapy, brain tumors, RNA and biomarker discovery, and he is an inventor on several patents. Dr. Skog earned his Master of Biomedical Sciences and Doctorate at Umeå University, Sweden.
Clinical Dx Showcase:
Exosome Diagnostics
Exosome Diagnostics, a leader in developing liquid biopsy-based diagnostics, is the first and only company that can simultaneously isolate and analyze exosomal RNA and cfDNA in a single step to achieve highest sensitivity for detecting rare mutations. ExosomeDx empowers the world’s leading biopharma companies in exploring this unique technology.
Exosomes: New Standard In Multi-Analyte Liquid Biopsy Testing
Session Abstract – PMWC 2022 Silicon Valley
The analysis of blood for circulating tumor cells (CTC), circulating tumor DNA (ctDNA), extracellular vesicles, or more recently, tumor-educated platelets has opened new avenues for cancer diagnostics, including early detection of tumors, improved risk assessment and staging, as well as early detection of relapse to improve patient care. The track will introduce the up-to-date technologies used in liquid biopsy and review the clinical utilities in cancer screening, detection of minimal residual diseases, selection of molecular-targeted drugs, as well as monitoring of treatment responsiveness.
Sessions:
- Early Cancer Detection- Status quo, Technical and Clinical Challenges, and the Future (PANEL)
Session Chair: Jimmy Lin, Freenome
- Peter Bach, Delfi Diagnostics
- Ash Alizadeh, Stanford
- Amir Ali Talasaz, Guardant Health
- Anne-Renee Hartman, Adela
- How is Liquid Biopsy Changing the Testing Paradigm for Oncology Patients? (PANEL)
Session Chair: Rebecca Brandes, Agilent
- Edward Abrahams, PMC
- Blandine Merino, Agilent
- Adrian Lee, UPMC - The Emerging Role of ctDNA for Molecular Residual Disease (MRD) Assessment and Recurrence Monitoring
- Minetta Liu, Natera - Liquid Biopsy for Screening, Diagnosis, Prognosis and Therapy Guidance
Session Chair: Sam Salman, miR Scientific
- Frederick Baehner, Exact Sciences
- The Advantages of Exosomes as a Liquid Biopsy Based Markers
Session Chair: Johan Skog, Exosome Diagnostics
- Jamil Azzi, Harvard
- Dolores Di Vizio, Cedars-Sinai Medical Center
- Showcase
- Dave Mullarkey, Bluestar Genomics
- Stephane Mouradian, Personalis
- Michael Dugan, Biocept
- Priti Hegde, Foundation Medicine
- Steven Soper, The University of Kansas
- Maggie Rougier-Chapman, Personal Genome Diagnostics
- Daniel Kim, UCSC
Session Abstract – PMWC 2022 Silicon Valley
Track 6 - June 28 9.00 A.M.-4.45 P.M.,Track 6 - June 29 3.30 P.M.-3.45 P.M.,Track 6 - June 30 9.00 A.M.-1.15 P.M.
The PMWC 2022 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Nerodegenerative
